Founded in India, with its long tradition of industrial entrepreneurship, Angiolife Healthcare has become one of the most progressive pharmaceutical company of Asia. At Angiolife Healthcare We create value in the full pharmaceutical value chain from developing to manufacturing and successfully marketing pharmaceuticals drugs and we take pride in doing this in an innovative, responsible and cost-efficient way. Angiolife Healthcare currently conducts operations in Pan INDIA and over the next few years, will also expand outside with the aim of becoming a global player.
Our corporate culture and close collaboration with development and manufacturing partners are integral parts of our effort to deliver quality products at affordable prices. We offer a product portfolio consisting of a broad range of high quality drugs for all major therapeutic areas. It is part of our long-term strategy to expand the product portfolio of off-patent blockbusters while at the same time offering a broader range of products within more narrow disease areas.
In Angiolife Healthcare products are originated where the efficacy and safety are well documented. Through our many collaborating partners, we have access to a vast range of technology platforms, enabling us to develop and enhance the intellectual property of our product portfolio.
Our strategy of developing products based on well-known substances with an improved value to patients results in a product portfolio with a significant market potential. We achieve this with a relatively short development time, low risk, and limited investment.
By focusing on innovation and simplicity in both thought and action, and by taking responsibility on all markets and cost efficiency in all stages, we are creating a strong and vibrant brand that offers quality pharmaceuticals at prices affordable to all.
Angiolife provides quality Medicines at affordable prices.
The Angiolife spirit is grounded on cost-consciousness, the willingness to assume responsibility and on innovative simplicity.
Angiolife 2020 is the name we have given to the growth strategy we have developed for the coming decade.